Abstract：
Anti-vascular endothelial growth factor (VEGF) drugs are widely used in modern ophthalmology, especially in treating macular disorders like age-related macular degeneration or diabetic macular edema. Protocols for such treatments include repeated administration of intravitreal injections, with the volume of drug injected into the vitreous chamber seemingly high enough to cause an increase in intraocular pressure. Hence, questions might arise if such therapeutic approaches are safe for ocular tissue. Moreover, anti-VEGF compounds may theoretically harm the retinal nerve fibers due to the inhibition of VEGF and its neuroprotective effects. Thus, this manuscript aims to review the literature regarding studies evaluating the retinal nerve fiber layer (RNFL) in eyes receiving anti-VEGF treatment due to age-related macular degeneration. The RNFL was chosen as a subject of this review, as it is the innermost retinal layer exposed to the direct action of intravitreally administered drugs. The results of the available studies remain inconclusive. Most researchers seem to confirm the safety of the anti-VEGF treatment in wet age-related macular degeneration, at least regarding the retinal nerve fiber layer. However, some authors noticed that the influence of anti-VEGFs on RNFL could become apparent after more than thirty injections. Nonetheless, the authors of all studies agree that further, long-term observations are needed to help clinicians understand the effect of anti-VEGF treatment on the dynamics of changes in the thickness of retinal nerve fibers in patients with the wet form of age-related macular degeneration.
摘要：
抗血管内皮生长因子(VEGF)药物广泛应用于现代眼科,尤其是治疗黄斑疾病，如年龄相关性黄斑变性或糖尿病性黄斑水肿。此类治疗的方案包括重复施用玻璃体内注射，注射到玻璃体腔中的药物量似乎高到足以引起眼内压升高。因此，如果这种治疗方法对眼组织是安全的，则可能会出现问题。此外，抗VEGF化合物在理论上可能由于VEGF的抑制及其神经保护作用而损害视网膜神经纤维。因此，本手稿旨在回顾有关评估因年龄相关性黄斑变性而接受抗VEGF治疗的眼视网膜神经纤维层(RNFL)的研究的文献.RNFL被选为这篇综述的主题，因为它是暴露于玻璃体内药物直接作用的最内层视网膜层。现有研究的结果仍然没有定论。大多数研究人员似乎证实了抗VEGF治疗湿性年龄相关性黄斑变性的安全性，至少关于视网膜神经纤维层.然而,一些作者注意到,抗VEGF对RNFL的影响在注射30次以上后可能变得明显.尽管如此，所有研究的作者都同意，需要进行长期观察,以帮助临床医师了解抗VEGF治疗对湿性年龄相关性黄斑变性患者视网膜神经纤维厚度动态变化的影响.
